The present invention provides compounds of Formula I:
wherein A is selected from the group consisting of;
R
1
is H or F;
R
2
is H, —CH
2
OH, C
1
-C
3
alkyl,
R
3
is H, F, or CN;
R
4
is H, F; or CN; and
R
5
is H, —CH
3
, or —OCH
3
;
or a pharmaceutically acceptable salt thereof.
[EN] A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR<br/>[FR] DÉRIVÉ DE TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE EN TANT QU'INHIBITEUR DE BACE
申请人:LILLY CO ELI
公开号:WO2016043996A1
公开(公告)日:2016-03-24
The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE imnhibitor).
Large-Scale Continuous Flow Transformation of Oximes into Fused-Bicyclic Isoxazolidines: An Example of Process Intensification
作者:Juan A. Rincón、Carlos Mateos、Pablo García-Losada、Dustin J. Mergott
DOI:10.1021/op500350y
日期:2015.2.20
Here, we report a continuous flow protocol for the [3 + 2] cycloaddition of nitrones, in situ generated from oximes, into bicyclic isoxazolidines. This thermal process required very high temperatures to be efficient that were not easily reached in conventional reactors. A couple of examples are presented and in both the flow process showed a greater performance than the batch mode. The process intensification study allowed the generation of 120 g/h of a key pharmaceutical intermediate.
Synthesis, Optimization, and Large-Scale Preparation of the Low-Dose Central Nervous System-Penetrant BACE1 Inhibitor LY3202626 via a [3 + 2] Nitrone Cycloaddition
作者:Pablo Garcia-Losada、Amy C. DeBaillie、Jose Eugenio de Diego、Steven J. Green、Marvin M. Hansen、Carlos Jaramillo、Matt Johnson、Talbi Kaoudi、Jiuyuan Li、Peter J. Lindsay-Scott、Carlos Mateos、Dustin J. Mergott、Juan Antonio Rincon、Roger R. Rothhaar、Kevin D. Seibert、Brian M. Watson、Leonard L. Winneroski、Srinivas Gangula、Dajiang Jing、Hao Sun、Lei Zhang、Michael O. Frederick
DOI:10.1021/acs.oprd.9b00471
日期:2020.2.21
Herein we report a summary of the synthetic development of LY3202626 from the initial discovery route to a final route that was scaled to make 150 kg. Key developments include the use of a [3 + 2] cyclization to set the cis ring junction of the formed isoxazoline, a one-pot thiazine formation, and three different ways to install the aniline: (1) Cu-catalyzed azide coupling and reduction, (2) nitration
[EN] TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE<br/>[FR] SEL DE TOSYLATE DE N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TÉTRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHÉNYL]-5-MÉTHOXY-PYRAZINE-2-CARBOXAMIDE
申请人:LILLY CO ELI
公开号:WO2016122968A1
公开(公告)日:2016-08-04
The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5- fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro- phenyl]-5-methoxy-pyrazine-2-carboxamide.